Everything drug pricing and policy, every day
Plus a look at whether access in Canada is being compromised in the era of MFN
And a German-government-backed MFN study exposes a contradiction at the heart of the U.S. approach to international prices
Plus links on the politics of MFN deals and the contribution of 340B to health-spending growth
And why CVS’ plan to split is unlikely to mollify critics
Plus CVS unveils plan to spin off its retail pharmacy business amidst policy pressures
And Alnylam faces down a 340B earthquake
And Medicare will pay $6 billion in illegal duplicate 340B discounts next year, IQVIA estimates